Reference
Direct Healthcare Professional Communication (DHPC): Ceftriaxone and Cefotaxime - Reminder of Precautions to Minimize Severe Hypersensitivity Reactions and Life-threatening Adverse Events Egyptian Pharmaceutical Vigilance Center Newsletter 14: No. 1, Jan 2023. Available from: URL: https://www.edaegypt.gov.eg/media/yfbdowoa/156-newsletter-hundred-fifty-six-january-2023-v3.pdf
Rights and permissions
About this article
Cite this article
Ceftriaxone- and cefotaxime-related severe hypersensitivity reactions. Reactions Weekly 1942, 2 (2023). https://doi.org/10.1007/s40278-023-32611-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-023-32611-7